Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Generation Bio Co. (GBIO)
NASDAQ:GBIO
Holding GBIO?
Track your performance easily
GBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.75 - $4.65
Previous Close$1.19
Volume884.88K
Average Volume (3M)219.83K
Market Cap
$72.14M
Enterprise Value-$18.85M
Total Cash (Recent Filing)$184.77M
Total Debt (Recent Filing)$93.78M
Price to Earnings (P/E)―
Beta3.50
Next Earnings
Feb 20, 2025EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding66,792,822
10 Day Avg. Volume1,424,557
30 Day Avg. Volume219,832
Standard Deviation0.31
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.76
Price to Sales (P/S)3.88
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.01
Enterprise Value/Gross Profit-3.19
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$9.50Price Target Upside698.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Generation Bio News
PremiumCompany Announcements
Generation Bio Co. Reports Q3 2024 Financials and Progress
Bulls Say, Bears Say
Bulls Say
Platform DevelopmentGeneration Bio is continuing development of iqDNA and ctLNPs, which are considered significant biological innovations.
Preclinical AdvancementsResults presented at the ESGCT meeting showcased preclinical advancements for Generation's mRNA selective immune (T-cell) delivery platform.
Strategic CollaborationGBIO is eligible to receive up to $1.8B in milestone payments upon specified achievements in collaboration with Moderna.
Bears Say
Cost ManagementAlthough cost-cutting measures are in place, the guidance for cash burn extends into the second half, raising concerns about financial efficiency.
Financial PerformanceA one-time lease termination led to an increased operating loss in the first quarter.
Program DevelopmentThe lack of a clear timeline for advancing the lead program into non-human primates or an investigational new drug application prompts analysts to maintain a Market Perform rating.
---
Ownership Overview
18.16% Insiders
24.43% Mutual Funds
32.45% Other Institutional Investors
17.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GBIO FAQ
What was Generation Bio Co.’s price range in the past 12 months?
Generation Bio Co. lowest stock price was $0.75 and its highest was $4.65 in the past 12 months.
What is Generation Bio Co.’s market cap?
Currently, no data Available
When is Generation Bio Co.’s upcoming earnings report date?
Generation Bio Co.’s upcoming earnings report date is Feb 20, 2025 which is in 60 days.
How were Generation Bio Co.’s earnings last quarter?
Generation Bio Co. released its earnings results on Nov 06, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.272 by $0.042.
Is Generation Bio Co. overvalued?
According to Wall Street analysts Generation Bio Co.’s price is currently Undervalued.
Does Generation Bio Co. pay dividends?
Generation Bio Co. does not currently pay dividends.
What is Generation Bio Co.’s EPS estimate?
Generation Bio Co.’s EPS estimate is -$0.3.
How many shares outstanding does Generation Bio Co. have?
Generation Bio Co. has 66,792,820 shares outstanding.
What happened to Generation Bio Co.’s price movement after its last earnings report?
Generation Bio Co. reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.272. Following the earnings report the stock price went down -0.833%.
Which hedge fund is a major shareholder of Generation Bio Co.?
Among the largest hedge funds holding Generation Bio Co.’s share is Baker Bros Advisors LP. It holds Generation Bio Co.’s shares valued at 5M.
---
Generation Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (698.32% Upside)
$9.50 (698.32% Upside)
Hedge Fund Trend
Increased
By 741.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.00%
12-Months-Change
Fundamentals
Return on Equity
-86.50%
Trailing 12-Months
Asset Growth
-34.79%
Trailing 12-Months
Company Description
Generation Bio Co.
Generation Bio Co is a genetics medicine company which is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.
---
GBIO Stock 12 Month Forecast
Average Price Target
$9.50
▲(698.32% Upside)
Technical Analysis
Best Analysts Covering GBIO
1 Year
---